Aviceda Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has cleared an IND for its lead intravitreal ocular asset AVD-104, paving the way for the company to initiate a Phase II trial. The drug will be assessed for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The phase trial, named SIGLEC trial, is expected to begin in Q2 2023.

AVD-104 is an intravitreal nanoparticle molecule that inhibits the activity of retinal macrophages and repolarises activated macrophages to their resolution state coupled with inhibition of complement cascade amplification.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This dual mechanism of action treats GA via modulation of inflammatory pathways, according to the Massachusetts, US-based company. Aviceda adds that the drug has demonstrated robust in-vitro/vivo efficacy with inhibition of both inflammatory & complement pathways and the potential for every 4-6-month dosing.

AMD is a cause of vision loss that affects 11 million people in the US. The dry form of AMD is characterised by the development of geographic atrophy (GA) where irreversible progressive destruction of central retinal cells and underlying blood vessels occur due to chronic inflammation.

“The FDA’s acceptance of our IND application to initiate the clinical evaluation of AVD-104 brings us one step closer to introducing a potentially paradigm-shifting treatment for people living with geographic atrophy and macular degeneration,” said Mohamed Genead, M.D., Aviceda’s co-founder, president & CEO.

“The AVD-104 IND clearance marks an important milestone for Aviceda as we continue our track record of execution as the leader in the glycome field. We are thrilled to advance the development of AVD-104 in the U.S. and are working to rapidly enroll patients in the Phase 2 portion of the study. We look forward to presenting additional data later this year.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact